Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

A Double-Blind, Randomized, Dose-finding Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

The purpose of this study is to investigate the optimal dose and administration methods of CJ-12420 in patients with erosive esophagitis by comparing the safety and efficacy of orally administered CJ-12420 to esomeprazole 40mg.

Inclusion Criteria:

• Aged between 20-70
• Diagnosed with Erosive Esophagitis by Esophagogastroduodenoscopy (EGD) and classified into LA Grade A to D within 14 days before randomization to treatment

Exclusion Criteria:

• Patients who cannot undergo EGD
• Patients diagnosed with irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or suspected IBS
• Patients who took PPIs within 2 weeks prior to study drug administration
• Long-term use of nonsteroidal anti-inflammatory drugs throughout the study
• Clinically significant abnormal laboratory values during screening